Trial Profile
A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2021
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Ocular inflammation; Ocular pain
- Focus Therapeutic Use
- Sponsors Bausch & Lomb; Bausch Health Companies; Valeant Pharmaceuticals International
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 29 Aug 2017 Status changed from recruiting to completed.
- 25 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.